Ovarian Cancer | Specialty

Mirvetuximab Soravtansine Shows Promise in Ovarian Cancer

June 12th 2017

Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853) induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.

Study Further Characterizes Niraparib PFS Benefit in Ovarian Cancer

June 9th 2017

Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian Cancer

June 9th 2017

In follow-up results to data first presented in December 2016, investigators found that the combination of olaparib (Lynparza) and cediranib maleate continued to show superior progression-free survival compared with olaparib alone for women with BRCA-negative recurrent platinum-sensitive ovarian cancer.

Dr. Barber on Neoadjuvant Chemotherapy in Ovarian Cancer

June 2nd 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.

Biotech Executive Offers Glimpse of Testing Future

May 27th 2017

Foundation Focus CDx BRCA, can detect both germline and somatic BRCA1/2 mutations in women with ovarian cancer who are candidates for the PARP inhibitor rucaparib (Rubraca).

Fresh Examples of Long Delays Highlight Need for Clinical Trial Reform

May 25th 2017

Randomization designed to isolate the impact of a specific factor has enabled practitioners to understand the value, or lack of value of particular drugs, procedures, or processes in a given clinical setting.

Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

May 23rd 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

Dr. Matulonis on Toxicities With PARP Inhibitors in Ovarian Cancer

May 23rd 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.

Bevacizumab Benefit Varies Among Ovarian Cancer Subtypes

May 19th 2017

Patients with proliferative or mesenchymal ovarian tumors treated with bevacizumab (Avastin) had superior progression-free survival and a trend toward improved overall survival compared with patients with immunoreactive or differentiated tumors.

Expert Discusses PARP Inhibitor Success in Ovarian Cancer

May 15th 2017

Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.

Bevacizumab Improves OS in Recurrent, Platinum-Sensitive Ovarian Cancer

May 6th 2017

Adding bevacizumab to standard platinum-based chemotherapy was associated with a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Novel Combo Shows Early Promise in Ovarian Cancer

May 5th 2017

Preclinical findings showed that the combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma ovarian tumor cells.

Dr. Muggia on Targeted Therapies for Ovarian Cancer

May 4th 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

Study Reveals Disparities in End-of-Life Care Among Ovarian Cancer Patients

May 3rd 2017

Within the last 30 days of life, black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care, according to results recently published in the Journal of Clinical Oncology.

Expert Discusses Immunotherapy Potential in Ovarian Cancer

May 2nd 2017

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Dr. Matulonis Discusses Maintenance in Ovarian Cancer

April 26th 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

Dr. Barber on Chemotherapy Versus Surgery for Ovarian Cancer

April 25th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

The Changing Landscape in Advanced Ovarian Cancer

April 24th 2017

Patient Selection for Bevacizumab in Ovarian Cancer

April 24th 2017

Ovarian Cancer: A New Indication for Bevacizumab

April 24th 2017